Key EU and UK regulatory changes to watch for in 2026

A number of ongoing legislative processes are likely to significantly impact the life sciences industry this year, writes Jackie Mulryne of Morgan Lewis.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Final call: Who are the world’s best in-house counsel?

16 January 2026 A first-of-its-kind project by sister title WIPR aims to highlight the world’s leading in-house intellectual property counsel—and it needs your help.

Europe

Italian medtech startup beats larger US rival in UPC dispute

15 January 2026 Case between AorticLab and Emboline has implications for UPC playbook in terms of requesting security for costs, and conditional counterclaims.

Europe

Bayer secures key Denmark ruling as Xarelto faces expiry pressure

13 January 2026 As the drug moves deeper into its post-exclusivity phase, a Nordic decision highlights the value of secondary patents, presumption of validity, and interim relief when a drug's core patents expire.

More features

Fed Circ overturns PTAB decision in $83.4m DNA case

AI is transforming top 100 innovators, shows index

Rooted rights: Lessons from plant patent infringement and invalidity cases

Skinny labels, big stakes: SCOTUS lines up the case of the year

Chinese biotech strikes billion dollar deal in nextgen cancer race

Final call: Who are the world’s best in-house counsel?

Italian medtech startup beats larger US rival in UPC dispute

Senior USPTO solicitor steps into private practice

Key EU and UK regulatory changes to watch for in 2026

More on this story

Editor's picks

Editor's picks

More features